Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling

INTRODUCTION: Castration‐resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration. Abiraterone, an inhibitor of the steroidogenic enzyme CYP17A1, has been demonstrated to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Moll, J. Matthijs, Hofland, Johannes, Teubel, Wilma J., de Ridder, Corina M. A., Taylor, Angela E., Graeser, Ralph, Arlt, Wiebke, Jenster, Guido W., van Weerden, Wytske M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306678/
https://www.ncbi.nlm.nih.gov/pubmed/35037287
http://dx.doi.org/10.1002/pros.24297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306678/
https://www.ncbi.nlm.nih.gov/pubmed/35037287
http://dx.doi.org/10.1002/pros.24297

Ejemplares similares